Continues Multi-Year Portfolio Simplification StrategyANTIOCH, Tenn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (Nasdaq: LKQ) today announced that it has commenced a process to explore the potential sale of its Specialty segment. “Our Specialty segment is a leading distributor of automotive, RV and marine parts and accessories in North America. It is a strong business supported by an exceptional team. To unlock its full potential, we initiated a strategic review earlier this year to evaluate opportu ...

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ...

Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private placement (see press release dated November 24, 2025) for gross proceeds of $140,000 (the "Private Placement"). Investors in the Private Placement subscribed for 1,244,441 units ("Units") at a price of $0.1125 per Unit. Each Unit consisted of one common s ...

Core Insights - Denali Therapeutics and Royalty Pharma have entered into a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa, Denali's lead investigational therapy for mucopolysaccharidosis type II (MPS II) [1][4] - The FDA is currently reviewing a Biologics License Application (BLA) for accelerated approval of tividenofusp alfa, with a target date of April 5, 2026 [2] Company Overview - Denali Therapeutics is focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle platform, aiming to address serious diseases including neurodegenerative and lysosomal storage disorders [6] - Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to leading pharmaceutical companies [7] Transaction Details - The agreement stipulates an initial payment of $200 million from Royalty Pharma, with an additional $75 million contingent upon achieving EMA approval by December 31, 2029 [4] - Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, with payments ceasing upon reaching a multiple of 3.0x or 2.5x if achieved by Q1 2039 [4] Leadership Statements - Denali's CEO, Ryan Watts, expressed optimism about the partnership with Royalty Pharma, highlighting the potential of tividenofusp alfa for the Hunter community and the broader implications for the TransportVehicle platform [3] - Royalty Pharma's CEO, Pablo Legorreta, emphasized the innovative nature of tividenofusp alfa and its potential to address significant unmet needs in Hunter syndrome [3]

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has signed its first ...

PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can ...

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced KODIAK COPPER CORP. (TSX-V: KDK; OTCQX: KDKCF), focused on the discovery of copper, has qualified to trade on the OTCQX® Best Market. KODIAK COPPER CORP. upgraded to OTCQX from the OTCQB® Venture Market. KODIAK COPPER CORP. begins trading today on OTCQX under the symbol “KDKCF.” U.S. investors can find current financial disclosu ...

For Repurchase of up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,346 Common Shares ("Shares"), that num ...

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers     REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated ...